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Cdk4 Inhibitors
Cyclins and cyclin-dependent kinases (Cdks) play important roles in regulation of the cell
cycle. In particular, D-type cyclins, which are activated by rearrangement or amplification in
several tumours, associate Cdk4/6. Cyclin D-Cdk4/6 complexes phosphorylate the
retinoblastoma protein (pRB) and regulate the cell cycle during G1/S transition. Loss of
function or deletion of p16ink4a (endogenous Cdk4/6 specific inhibitor protein) frequently
occurs in clinical cancer cells. As a next generation of Cdk inhibitors, selective inhibitors of
only one target Cdk are expected to cause cell cycle arrest specifically. Suppression of tumour
growth by G1 arrest is thought to reduce the stress for normal cells more than in other phases,
because normal cells are usually resting in the G0-G1 phase. Thus, the design of Cdk4 selective
inhibitors that cause cell cycle arrest in the G1 phase has been attempted [2] (Structure-based
generation of a new class of potent Cdk4 inhibitors: New de novo design strategy and library
design, Honma, T. et. al., J. Med. Chem., 44, (2001), 4615-4627). To obtain highly selective
and potent Cdk4 inhibitors a structure-based design was performed which consisted of lead
generation of a new class of Cdk4 inhibitors based on a Cdk4 homology model, and
enhancement of Cdk4 selectivity of lead compounds over Cdk1/2 and other kinases based on
the binding modes and structural differences between Cdk4 and other kinases. This
methodology was applied to search the Available Chemicals Directory and 382 commercial
compounds were selected for screening in cyclin D-Cdk4 assays at concentrations up to 1mM.
From this set, 18 compounds were found which possessed an IC50 value of under 500 µM.
From these hits, a class of diarylureas were identified with the potential for parallel synthesis
follow up to validate the potential of the scaffold and to obtain preliminary SAR. 410 Urea
compounds were then designed and synthesised as singles in solution, the design based on the
diarylurea hits, and they were screened in a Cdk4 inhibition assay. One of the most potent
compounds isolated was (i) which possessed an IC50 value of 34 nM. This work has utilised a
structure-based lead generation approach consisting of homology modelling of the target
protein, construction of a library of compounds, followed by modification of hits obtained
based on predicted binding mode. This strategy has provided potent compounds from a new
class of diarylurea Cdk4 inhibitors and may lay the foundation for further work to improve
potency in this series.
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17β-Hydroxysteroid dehydrogenase Inhibitors
Type 3 17β-hydroxysteroid dehydrogenase (17β-HSD) is a steroidogenic enzyme that
catalyses the reduction of 4-androstene-3,17-one (∆4-dione) to testosterone using reduced
nicotinamide adenine dinucleotide phosphate (NADPH) as the cofactor. This third member of
the 17β-HSD enzyme family is found almost exclusively in the testis and contributes to the
production of approximately 60% of total active androgens in men. The inhibition in the testis
of type 3 17β-HSD and the inhibition in peripheral tissues of other key enzymes such as 5α-
reductases, represent interesting strategies toward a complete blockade of the biosynthesis of
androgens T and dihydrotestosterone (DHT). In the case of hormone sensitive diseases such
as prostate cancer, obtaining a complete androgen blockade is crucial to counter the
proliferation effect of androgens on prostate cancer cells. To achieve an optimal blockage of
androgen formation, a potent inhibitor of type 3 17β-HSD was sought by parallel library
synthesis (Synthesis and optimisation of a new family of type 3 17β-hydroxysteroid
dehydrogenase inhibitors by parallel liquid-phase chemistry, Poirier, D. et. al., J. Med. Chem.,
45, (2002), 640-653). A total of four libraries comprising 298 single compounds were
synthesised in solution. The library compounds were screened for their ability to inhibit the
type 3 17β-HSD activity in transfected in human embryonic kidney (HEK)-293 cells. One of
the most potent compounds found was (ii) which possessed an IC50 of 35 nM which is 18-fold
higher than that of the natural substrate of the enzyme, ∆4-dione. This work has provided a
library steroid derivatives as potentially a new class of inhibitors of type 3 17β-HSD.
O
OH
N
O
(ii)
Thrombin receptor (PAR-1) antagonists
Thrombin receptors are attractive drug discovery targets because they mediate a variety of
cellular actions of thrombin, such as platelet aggregation, lymphocyte mitosis, monocyte
chemotaxis, and endothelial cell proliferation. The first example of a thrombin receptor
(protease-activated receptor 1, PAR-1) was identified as a member of the superfamily of
seven-transmembrane, G-protein-coupled receptors. Thrombin activates PAR-1 by proteolytic
cleavage of the N-terminal extracellular domain between Agr-41 and Ser-42 to reveal a new
N-terminus containing the activated motif SFLLRN, which serves as a ‘tethered’ peptide
ligand. Since PAR-1 mediates many cellular actions of thrombin, a PAR-1 antagonist may
have therapeutic potential for treating various disorders, such as thrombosis, restenosis and
stroke. The identification of potent and selective PAR-1 antagonists has proved to be
challenging. This situation is partially due to the unfavourable entropy for an external ligand to
compete with a tethered ligand. Of the PAR-1 antagonists reported, several have notable
deficiencies such as weak potency, inability to inhibit thrombin-induced platelet aggregation
consistently, mixed agonist-antagonist activity, and/or lack of PAR selectivity. Through a de
novo design approach, a series of novel indole-based SFLLR peptide mimetics as potent and
selective PAR-1 antagonists have been discovered (Thrombin receptor (PAR-1) antagonists.
Solid-phase synthesis of indole-based peptide mimetics by anchoring to a secondary amide,
Zhang, H-C. et. al., Bioorg. Med. Chem. Lett., 11, (2001), 2105-2109).
A library of over 200 single compounds was synthesised on a Sieber amide solid phase resin.
The library compounds were screened for their ability to inhibit platelet aggregation induced
by thrombin, SFLLRN-NH2, collagen and a thromboxane mimetic U46619. One of the most
potent compounds isolated was (iii) which possessed an IC50 value of 340 nM against
thrombin and was also inactive against collagen and U46619. This work has generated rapid
SAR and the identification of potent and selective indole-based peptide mimetics as PAR-1
antagonists, work that could provide the basis for further development of PAR-1 antagonists.
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